BIONTECH SE SPON. ADRS 1
Commented by Mario Hose on September 29th, 2020 | 10:51 CEST
BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results
Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.
Read
Commented by Mario Hose on September 28th, 2020 | 10:15 CEST
BioNTech, NEL ASA, Silver Viper: Profit lies in purchasing
As is well known, timing is of paramount importance for the stock market. Investors who look to take a position always look for the best possible entry point. Rarely do even experienced stock market traders succeed in hitting the low point before the price rises. In connection with the current Corona Pandemic and the uncertainties as to how the course of a possible second wave of infection will develop, there have already been considerable price fluctuations and entry opportunities on the stock markets in recent weeks.
Read
Commented by Mario Hose on September 23rd, 2020 | 09:05 CEST
BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?
When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.
Read
Commented by Mario Hose on September 18th, 2020 | 06:00 CEST
BioNTech, CureVac, EXMceuticals - reaching their goal with government support
In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.
Read
Commented by Mario Hose on September 11th, 2020 | 09:59 CEST
BioNTech, CureVac, Valeo Pharma - Growth after capital injection
Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.
Read
Commented by Mario Hose on September 1st, 2020 | 11:56 CEST
BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry
In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the potential to close a lucrative deal, because a lot is at stake for politics and economy. The necessary tests are carried out at great expense in order not to endanger human life through a vaccination, but to protect it. There are great opportunities for investors.
Read
Commented by Mario Hose on August 24th, 2020 | 06:58 CEST
BioNTech, CureVac, Valeo Pharma - the license to print money
Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because there is enormous pressure to act from all sides. The sooner vaccines or other products are available, the sooner it will be possible to return to normal everyday life. While two German pharmaceutical companies are investing a lot of money in researching a vaccine, a Canadian competitor is taking an equally exciting and less risky route.
Read
Commented by Mario Hose on August 18th, 2020 | 06:00 CEST
BioNTech, CureVac, Valeo Pharma - who is the Covid-19 winner?
The two German companies BioNTech and CureVac have already provided investors with a considerable boost in share prices. The companies have come into the public eye in recent months because they are working on a vaccine against Covid-19 and have already made great progress. Worldwide, these two companies belong to the elite in research and are a beacon of hope in the fight against the corona pandemic. While BioNTech has been listed on the stock exchange for some time, CureVac made its stock market debut last Friday - with success. Investors who have so far missed their entry in these companies should have Valeo Pharma at least on their watch list.
Read
Commented by Mario Hose on July 29th, 2020 | 07:29 CEST
BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit
The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.
Read
Commented by Mario Hose on July 15th, 2020 | 12:23 CEST
BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential
In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.
Read